Neumora Therapeutics Shares Plummet on Monday

Biotech stock drops over 20% as investors react to latest developments

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Shares of Neumora Therapeutics (NASDAQ:NMRA), a clinical-stage biopharmaceutical company focused on developing precision therapies for central nervous system disorders, fell sharply on Monday, opening at $2.85 after closing at $3.49 the previous trading day. The stock closed at $3.14, down over 10% for the day, on heavy trading volume of over 1 million shares.

Why it matters

Neumora Therapeutics is a closely watched biotech company in the neuroscience space, and its stock performance is seen as an indicator of investor sentiment around its pipeline of experimental treatments. The significant drop in share price suggests potential concerns about the company's progress or future prospects.

The details

The reasons behind the stock's decline are not entirely clear, but analysts have cited a range of factors that may be weighing on investor sentiment, including mixed clinical data, regulatory hurdles, and increased competition in the company's target markets.

  • Neumora Therapeutics' shares opened at $2.85 on Monday, March 2, 2026, down from a previous close of $3.49.
  • The stock closed at $3.14 on Monday, March 2, 2026, representing a decline of over 10% for the day.

The players

Neumora Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing precision therapies for central nervous system disorders, headquartered in Cambridge, Massachusetts.

Paul L. Berns

An insider at Neumora Therapeutics who sold 9,819 shares of the company's stock on February 17, 2026.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The sharp decline in Neumora Therapeutics' stock price highlights the volatility and uncertainty inherent in the biotech industry, where the success or failure of experimental therapies can have a significant impact on a company's valuation. Investors will be closely watching the company's future developments and clinical trial results to gauge its long-term prospects.